PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2147155
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2147155
Fertility Drugs Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034
Growth Factors of fertility drugs Market
The global fertility drugs market size was valued at USD 3.05 billion in 2025 and is projected to grow from USD 3.24 billion in 2026 to USD 5.25 billion by 2034, exhibiting a CAGR of 6.22% during the 2026-2034 forecast period. North America dominated the market with a 34.1% share in 2025, representing a regional market value of approximately USD 1.04 billion.
Fertility drugs are medicines used to regulate reproductive hormones, stimulate ovulation, support follicle and egg development, and improve outcomes in assisted reproductive procedures such as IVF and IUI. They are widely used for ovulatory disorders, unexplained infertility, polycystic ovary syndrome, diminished ovarian reserve, and controlled ovarian stimulation. Rising infertility prevalence, delayed parenthood, growing awareness, and wider access to fertility clinics are supporting market expansion.
Fertility Drugs Market Trends
Early Infertility Diagnosis and Treatment Awareness Gain Importance
Growing awareness of infertility as a common reproductive health condition is encouraging more patients to seek diagnosis and treatment. Increasing use of ovulation induction therapies, gonadotropins, hormonal treatments, and luteal phase support medicines is strengthening product demand.
The expansion of fertility benefits and affordability programs is another important trend. Government initiatives, employer-supported healthcare benefits, and pharmaceutical access programs are helping reduce medication costs and improve treatment availability.
Market Drivers
Delayed Parenthood and Rising Maternal Age Drive Demand
Increasing maternal age is a major market driver as more individuals postpone parenthood due to education, careers, economic considerations, and changing family preferences. As fertility naturally declines with age, demand is rising for ovulation induction, controlled ovarian stimulation, IVF, and IUI treatments.
Growing ART procedure volumes, expanding fertility clinic networks, and continued drug pipeline development are also contributing to market growth.
Market Restraints
Safety Concerns Associated with Hormonal Stimulation Limit Adoption
Fertility medicines, particularly gonadotropins used during ovarian stimulation, can cause adverse effects such as ovarian hyperstimulation syndrome. These risks require careful patient monitoring and specialist supervision.
High out-of-pocket costs, uneven reimbursement, and limited access to specialist reproductive healthcare may further restrict adoption, particularly in developing markets.
Market Opportunities
Employer and Insurance Fertility Benefits Create Opportunities
Expansion of fertility coverage through employers and insurers presents significant growth potential. Reduced out-of-pocket medication expenses can encourage patients to begin and continue fertility treatment.
Greater reimbursement support can also increase utilization of IVF-related fertility drugs, creating opportunities for manufacturers, pharmacies, and fertility care providers.
Market Challenges
Uncertain treatment success remains a major challenge. Fertility treatments do not guarantee pregnancy or live birth, and some patients require multiple cycles. Repeated treatment increases medication costs, emotional stress, and treatment fatigue, which may cause patients to delay or discontinue therapy.
Segmentation Analysis
By drug class, gonadotropins dominate due to their central role in controlled ovarian stimulation. The others category is projected to grow at an 8.04% CAGR.
By drug, FSH held the largest market share in 2025 because of its extensive use in follicle development and IVF protocols. Cetrorelix is projected to grow at a 9.47% CAGR.
By treatment, ART/IVF cycle support dominates as fertility medicines are required across ovarian stimulation, ovulation triggering, egg retrieval preparation, and luteal support. Male fertility treatment is projected to grow at a 6.86% CAGR.
By route of administration, injectable drugs dominate due to precise dosing and widespread use of gonadotropins and trigger medicines. The others segment is projected to grow at a 10.48% CAGR.
By end user, fertility clinics led the market in 2025, while specialty clinics are projected to expand at a 7.01% CAGR.
Regional Outlook
North America led with USD 1.04 billion in 2025. The U.S. market is estimated to reach USD 1.03 billion in 2026, representing approximately 31.71% of global revenues.
Europe is projected to reach USD 0.87 billion in 2026 and grow at a 5.27% CAGR. Germany and the U.K. are estimated at USD 0.20 billion and USD 0.18 billion, respectively.
Asia Pacific is expected to reach USD 0.89 billion in 2026. China, Japan, and India are projected at approximately USD 0.27 billion, USD 0.19 billion, and USD 0.12 billion, respectively.
Latin America is projected to reach USD 0.19 billion in 2026, while the GCC fertility drugs market is estimated at USD 0.07 billion. South Africa is projected at approximately USD 0.02 billion.
Competitive Landscape
Major companies include Merck KGaA, Ferring B.V., Organon & Co., IBSA Institut Biochimique SA, Gedeon Richter, Theramex, Livzon Pharmaceutical Group, LG Chem, Bharat Serums and Vaccines, and Lupin Limited. Competition centers on injectable fertility therapies, biosimilars, regulatory approvals, product pipelines, affordability initiatives, and geographic expansion.
Key Industry Developments
In February 2026, EMD Serono expanded access pathways for its IVF medicines, including Gonal-f, Ovidrel, and Cetrotide, in the U.S. In 2025, Ferring advanced follitropin delta research, Organon expanded its fertility manufacturing presence, and Gedeon Richter collaborated with Granata Bio on recombinant FSH development.
Conclusion
The fertility drugs market is expected to maintain steady growth as delayed parenthood, infertility awareness, ART adoption, and fertility clinic expansion increase worldwide. The market is projected to rise from USD 3.05 billion in 2025 to USD 3.24 billion in 2026 and reach USD 5.25 billion by 2034, growing at a 6.22% CAGR. Broader fertility benefits, improved treatment access, drug innovation, and rising IVF utilization will remain the major factors shaping market growth through 2034.
Segmentation By Drug Class, Drug, Treatment, Route of Administration, End User, and Region
By Drug Class
- Ovulation Induction Agents
- Gonadotropins
- hCG-based Trigger Drugs
- GnRH Agonists
- GnRH Antagonists
- Progesterone/Luteal Phase Support Drugs
- Others
By Drug
- Clomiphene Citrate
- Letrozole
- FSH
- hMG
- hCG
- Progesterone
- Cetrorelix
- Ganirelix
- Leuprolide
- Triptorelin
- Others
By Treatment
- ART/IVF Cycle Support
- Non-ART Female Fertility Treatment
- Male Fertility Treatment
By Route of Administration
- Injectable
- Oral
- Vaginal
- Others
By End User
- Fertility Clinics
- Hospitals
- Specialty Clinics
- Homecare/Self-administration Settings
- Others
By Region
- North America (By Drug Class, Drug, Treatment, Route of Administration, End User, and Country)
- U.S.
- Canada
- Europe (By Drug Class, Drug, Treatment, Route of Administration, End User, and Country/Sub-region)
- Germany
- U.K.
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific (By Drug Class, Drug, Treatment, Route of Administration, End User, and Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Drug Class, Drug, Treatment, Route of Administration, End User, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Drug Class, Drug, Treatment, Route of Administration, End User, and Country/Sub-region)
- GCC
- South Africa
- Rest of Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
- 3.5. Market Challenges
4. Key Insights
- 4.1. Prevalence of Key Fertility Disorders, By Key Regions, Countries
- 4.2. Pipeline Analysis, By Key Players
- 4.3. Overview of Regulatory Scenario, By Key Regions/Countries
- 4.4. New Product Launches, By Key Players
- 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
5. Global Fertility Drugs Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Drug Class
- 5.1.1. Ovulation Induction Agents
- 5.1.2. Gonadotropins
- 5.1.3. hCG-based Trigger Drugs
- 5.1.4. GnRH Agonists
- 5.1.5. GnRH Antagonists
- 5.1.6. Progesterone/Luteal Phase Support Drugs
- 5.1.7. Others
- 5.2. Market Analysis, Insights and Forecast - By Drug
- 5.2.1. Clomiphene Citrate
- 5.2.2. Letrozole
- 5.2.3. FSH
- 5.2.4. hMG
- 5.2.5. hCG
- 5.2.6. Progesterone
- 5.2.7. Cetrorelix
- 5.2.8. Ganirelix
- 5.2.9. Leuprolide
- 5.2.10. Triptorelin
- 5.2.11. Others
- 5.3. Market Analysis, Insights and Forecast - By Treatment
- 5.3.1. ART/IVF Cycle Support
- 5.3.2. Non-ART Female Fertility Treatment
- 5.3.3. Male Fertility Treatment
- 5.4. Market Analysis, Insights and Forecast - By Route of Administration
- 5.4.1. Injectable
- 5.4.2. Oral
- 5.4.3. Vaginal
- 5.4.4. Others
- 5.5. Market Analysis, Insights and Forecast - By End User
- 5.5.1. Fertility Clinics
- 5.5.2. Hospitals
- 5.5.3. Specialty Clinics
- 5.5.4. Homecare/Self-administration Settings
- 5.5.5. Others
- 5.6. Market Analysis, Insights and Forecast - Region
- 5.6.1. North America
- 5.6.2. Europe
- 5.6.3. Asia Pacific
- 5.6.4. Latin America
- 5.6.5. Middle East & Africa
6. North America Fertility Drugs Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Drug Class
- 6.1.1. Ovulation Induction Agents
- 6.1.2. Gonadotropins
- 6.1.3. hCG-based Trigger Drugs
- 6.1.4. GnRH Agonists
- 6.1.5. GnRH Antagonists
- 6.1.6. Progesterone/Luteal Phase Support Drugs
- 6.1.7. Others s
- 6.2. Market Analysis, Insights and Forecast - By Drug
- 6.2.1. Clomiphene Citrate
- 6.2.2. Letrozole
- 6.2.3. FSH
- 6.2.4. hMG
- 6.2.5. hCG
- 6.2.6. Progesterone
- 6.2.7. Cetrorelix
- 6.2.8. Ganirelix
- 6.2.9. Leuprolide
- 6.2.10. Triptorelin
- 6.2.11. Others
- 6.3. Market Analysis, Insights and Forecast - By Treatment
- 6.3.1. ART/IVF Cycle Support
- 6.3.2. Non-ART Female Fertility Treatment
- 6.3.3. Male Fertility Treatment
- 6.4. Market Analysis, Insights and Forecast - By Route of Administration
- 6.4.1. Injectable
- 6.4.2. Oral
- 6.4.3. Vaginal
- 6.4.4. Others
- 6.5. Market Analysis, Insights and Forecast - By End User
- 6.5.1. Fertility Clinics
- 6.5.2. Hospitals
- 6.5.3. Specialty Clinics
- 6.5.4. Homecare/Self-administration Settings
- 6.5.5. Others
- 6.6. Market Analysis, Insights and Forecast - By Country
- 6.6.1. U.S.
- 6.6.2. Canada
7. Europe Fertility Drugs Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Drug Class
- 7.1.1. Ovulation Induction Agents
- 7.1.2. Gonadotropins
- 7.1.3. hCG-based Trigger Drugs
- 7.1.4. GnRH Agonists
- 7.1.5. GnRH Antagonists
- 7.1.6. Progesterone/Luteal Phase Support Drugs
- 7.1.7. Others s
- 7.2. Market Analysis, Insights and Forecast - By Drug
- 7.2.1. Clomiphene Citrate
- 7.2.2. Letrozole
- 7.2.3. FSH
- 7.2.4. hMG
- 7.2.5. hCG
- 7.2.6. Progesterone
- 7.2.7. Cetrorelix
- 7.2.8. Ganirelix
- 7.2.9. Leuprolide
- 7.2.10. Triptorelin
- 7.2.11. Others
- 7.3. Market Analysis, Insights and Forecast - By Treatment
- 7.3.1. ART/IVF Cycle Support
- 7.3.2. Non-ART Female Fertility Treatment
- 7.3.3. Male Fertility Treatment
- 7.4. Market Analysis, Insights and Forecast - By Route of Administration
- 7.4.1. Injectable
- 7.4.2. Oral
- 7.4.3. Vaginal
- 7.4.4. Others
- 7.5. Market Analysis, Insights and Forecast - By End User
- 7.5.1. Fertility Clinics
- 7.5.2. Hospitals
- 7.5.3. Specialty Clinics
- 7.5.4. Homecare/Self-administration Settings
- 7.5.5. Others
- 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.6.1. U.K.
- 7.6.2. Germany
- 7.6.3. France
- 7.6.4. Italy
- 7.6.5. Spain
- 7.6.6. Scandinavia
- 7.6.7. Rest of Europe
8. Asia Pacific Fertility Drugs Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Drug Class
- 8.1.1. Ovulation Induction Agents
- 8.1.2. Gonadotropins
- 8.1.3. hCG-based Trigger Drugs
- 8.1.4. GnRH Agonists
- 8.1.5. GnRH Antagonists
- 8.1.6. Progesterone/Luteal Phase Support Drugs
- 8.1.7. Others s
- 8.2. Market Analysis, Insights and Forecast - By Drug
- 8.2.1. Clomiphene Citrate
- 8.2.2. Letrozole
- 8.2.3. FSH
- 8.2.4. hMG
- 8.2.5. hCG
- 8.2.6. Progesterone
- 8.2.7. Cetrorelix
- 8.2.8. Ganirelix
- 8.2.9. Leuprolide
- 8.2.10. Triptorelin
- 8.2.11. Others
- 8.3. Market Analysis, Insights and Forecast - By Treatment
- 8.3.1. ART/IVF Cycle Support
- 8.3.2. Non-ART Female Fertility Treatment
- 8.3.3. Male Fertility Treatment
- 8.4. Market Analysis, Insights and Forecast - By Route of Administration
- 8.4.1. Injectable
- 8.4.2. Oral
- 8.4.3. Vaginal
- 8.4.4. Others
- 8.5. Market Analysis, Insights and Forecast - By End User
- 8.5.1. Fertility Clinics
- 8.5.2. Hospitals
- 8.5.3. Specialty Clinics
- 8.5.4. Homecare/Self-administration Settings
- 8.5.5. Others
- 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.6.1. China
- 8.6.2. Japan
- 8.6.3. India
- 8.6.4. Southeast Asia
- 8.6.5. Australia
- 8.6.6. Rest of Asia Pacific
9. Latin America Fertility Drugs Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Drug Class
- 9.1.1. Ovulation Induction Agents
- 9.1.2. Gonadotropins
- 9.1.3. hCG-based Trigger Drugs
- 9.1.4. GnRH Agonists
- 9.1.5. GnRH Antagonists
- 9.1.6. Progesterone/Luteal Phase Support Drugs
- 9.1.7. Others s
- 9.2. Market Analysis, Insights and Forecast - By Drug
- 9.2.1. Clomiphene Citrate
- 9.2.2. Letrozole
- 9.2.3. FSH
- 9.2.4. hMG
- 9.2.5. hCG
- 9.2.6. Progesterone
- 9.2.7. Cetrorelix
- 9.2.8. Ganirelix
- 9.2.9. Leuprolide
- 9.2.10. Triptorelin
- 9.2.11. Others
- 9.3. Market Analysis, Insights and Forecast - By Treatment
- 9.3.1. ART/IVF Cycle Support
- 9.3.2. Non-ART Female Fertility Treatment
- 9.3.3. Male Fertility Treatment
- 9.4. Market Analysis, Insights and Forecast - By Route of Administration
- 9.4.1. Injectable
- 9.4.2. Oral
- 9.4.3. Vaginal
- 9.4.4. Others
- 9.5. Market Analysis, Insights and Forecast - By End User
- 9.5.1. Fertility Clinics
- 9.5.2. Hospitals
- 9.5.3. Specialty Clinics
- 9.5.4. Homecare/Self-administration Settings
- 9.5.5. Others
- 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.6.1. Brazil
- 9.6.2. Mexico
- 9.6.3. Rest of Latin America
10. Middle East & Africa Fertility Drugs Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Drug Class
- 10.1.1. Ovulation Induction Agents
- 10.1.2. Gonadotropins
- 10.1.3. hCG-based Trigger Drugs
- 10.1.4. GnRH Agonists
- 10.1.5. GnRH Antagonists
- 10.1.6. Progesterone/Luteal Phase Support Drugs
- 10.1.7. Others s
- 10.2. Market Analysis, Insights and Forecast - By Drug
- 10.2.1. Clomiphene Citrate
- 10.2.2. Letrozole
- 10.2.3. FSH
- 10.2.4. hMG
- 10.2.5. hCG
- 10.2.6. Progesterone
- 10.2.7. Cetrorelix
- 10.2.8. Ganirelix
- 10.2.9. Leuprolide
- 10.2.10. Triptorelin
- 10.2.11. Others
- 10.3. Market Analysis, Insights and Forecast - By Treatment
- 10.3.1. ART/IVF Cycle Support
- 10.3.2. Non-ART Female Fertility Treatment
- 10.3.3. Male Fertility Treatment
- 10.4. Market Analysis, Insights and Forecast - By Route of Administration
- 10.4.1. Injectable
- 10.4.2. Oral
- 10.4.3. Vaginal
- 10.4.4. Others
- 10.5. Market Analysis, Insights and Forecast - By End User
- 10.5.1. Fertility Clinics
- 10.5.2. Hospitals
- 10.5.3. Specialty Clinics
- 10.5.4. Homecare/Self-administration Settings
- 10.5.5. Others
- 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.6.1. GCC
- 10.6.2. South Africa
- 10.6.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. Merck KGaA
- 11.2.2. Ferring B.V.
- 11.2.3. Organon & Co.
- 11.2.4. IBSA Institut Biochimique SA
- 11.2.5. Gedeon Richter Plc.
- 11.2.6. Theramex
- 11.2.7. Livzon Pharmaceutical Group
- 11.2.8. LG Chem
- 11.2.9. Bharat Serums and Vaccines
- 11.2.10. Lupin Limited.
List of Tables
- Table 1: Global Fertility Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 2: Global Fertility Drugs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
- Table 3: Global Fertility Drugs Market Revenue (USD billion) Forecast, by Treatment, 2021-2034
- Table 4: Global Fertility Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 5: Global Fertility Drugs Market Revenue (USD billion) Forecast, by End User, 2021-2034
- Table 6: Global Fertility Drugs Market Revenue (USD billion) Forecast, by Region, 2021-2034
- Table 7: North America Fertility Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 8: North America Fertility Drugs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
- Table 9: North America Fertility Drugs Market Revenue (USD billion) Forecast, by Treatment, 2021-2034
- Table 10: North America Fertility Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 11: North America Fertility Drugs Market Revenue (USD billion) Forecast, by End User, 2021-2034
- Table 12: North America Fertility Drugs Market Revenue (USD billion) Forecast, by Country, 2021-2034
- Table 13: Europe Fertility Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 14: Europe Fertility Drugs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
- Table 15: Europe Fertility Drugs Market Revenue (USD billion) Forecast, by Treatment, 2021-2034
- Table 16: Europe Fertility Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 17: Europe Fertility Drugs Market Revenue (USD billion) Forecast, by End User, 2021-2034
- Table 18: Europe Fertility Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
- Table 19: Asia Pacific Fertility Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 20: Asia Pacific Fertility Drugs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
- Table 21: Asia Pacific Fertility Drugs Market Revenue (USD billion) Forecast, by Treatment, 2021-2034
- Table 22: Asia Pacific Fertility Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 23: Asia Pacific Fertility Drugs Market Revenue (USD billion) Forecast, by End User, 2021-2034
- Table 24: Asia Pacific Fertility Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
- Table 25: Latin America Fertility Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 26: Latin America Fertility Drugs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
- Table 27: Latin America Fertility Drugs Market Revenue (USD billion) Forecast, by Treatment, 2021-2034
- Table 28: Latin America Fertility Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 29: Latin America Fertility Drugs Market Revenue (USD billion) Forecast, by End User, 2021-2034
- Table 30: Latin America Fertility Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
- Table 31: Middle East & Africa Fertility Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 32: Middle East & Africa Fertility Drugs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
- Table 33: Middle East & Africa Fertility Drugs Market Revenue (USD billion) Forecast, by Treatment, 2021-2034
- Table 34: Middle East & Africa Fertility Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 35: Middle East & Africa Fertility Drugs Market Revenue (USD billion) Forecast, by End User, 2021-2034
- Table 36: Middle East & Africa Fertility Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
List of Figures
- Figure 1: Global Fertility Drugs Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
- Figure 2: Global Fertility Drugs Market Value Share (%), by Drug Class, 2025 & 2034
- Figure 3: Global Fertility Drugs Market Value Share (%), by Drug, 2025 & 2034
- Figure 4: Global Fertility Drugs Market Value Share (%), by Treatment, 2025 & 2034
- Figure 5: Global Fertility Drugs Market Value Share (%), by Route of Administration, 2025 & 2034
- Figure 6: Global Fertility Drugs Market Value Share (%), by End User, 2025 & 2034
- Figure 7: Global Fertility Drugs Market Value Share (%), by Region, 2025 & 2034
- Figure 8: North America Fertility Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 9: North America Fertility Drugs Market Value Share (%), by Drug Class, 2025
- Figure 10: North America Fertility Drugs Market Value (USD billion), by Drug, 2025 & 2034
- Figure 11: North America Fertility Drugs Market Value Share (%), by Drug, 2025
- Figure 12: North America Fertility Drugs Market Value (USD billion), by Treatment, 2025 & 2034
- Figure 13: North America Fertility Drugs Market Value Share (%), by Treatment, 2025
- Figure 14: North America Fertility Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 15: North America Fertility Drugs Market Value Share (%), by Route of Administration, 2025
- Figure 16: North America Fertility Drugs Market Value (USD billion), by End User, 2025 & 2034
- Figure 17: North America Fertility Drugs Market Value Share (%), by End User, 2025
- Figure 18: North America Fertility Drugs Market Value (USD billion), by Country, 2025 & 2034
- Figure 19: North America Fertility Drugs Market Value Share (%), by Country, 2025
- Figure 20: Europe Fertility Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 21: Europe Fertility Drugs Market Value Share (%), by Drug Class, 2025
- Figure 22: Europe Fertility Drugs Market Value (USD billion), by Drug, 2025 & 2034
- Figure 23: Europe Fertility Drugs Market Value Share (%), by Drug, 2025
- Figure 24: Europe Fertility Drugs Market Value (USD billion), by Treatment, 2025 & 2034
- Figure 25: Europe Fertility Drugs Market Value Share (%), by Treatment, 2025
- Figure 26: Europe Fertility Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 27: Europe Fertility Drugs Market Value Share (%), by Route of Administration, 2025
- Figure 28: Europe Fertility Drugs Market Value (USD billion), by End User, 2025 & 2034
- Figure 29: Europe Fertility Drugs Market Value Share (%), by End User, 2025
- Figure 30: Europe Fertility Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 31: Europe Fertility Drugs Market Value Share (%), by Country/ Sub-region, 2025
- Figure 32: Asia Pacific Fertility Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 33: Asia Pacific Fertility Drugs Market Value Share (%), by Drug Class, 2025
- Figure 34: Asia Pacific Fertility Drugs Market Value (USD billion), by Drug, 2025 & 2034
- Figure 35: Asia Pacific Fertility Drugs Market Value Share (%), by Drug, 2025
- Figure 36: Asia Pacific Fertility Drugs Market Value (USD billion), by Treatment, 2025 & 2034
- Figure 37: Asia Pacific Fertility Drugs Market Value Share (%), by Treatment, 2025
- Figure 38: Asia Pacific Fertility Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 39: Asia Pacific Fertility Drugs Market Value Share (%), by Route of Administration, 2025
- Figure 40: Asia Pacific Fertility Drugs Market Value (USD billion), by End User, 2025 & 2034
- Figure 41: Asia Pacific Fertility Drugs Market Value Share (%), by End User, 2025
- Figure 42: Asia Pacific Fertility Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 43: Asia Pacific Fertility Drugs Market Value Share (%), by Country/ Sub-region, 2025
- Figure 44: Latin America Fertility Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 45: Latin America Fertility Drugs Market Value Share (%), by Drug Class, 2025
- Figure 46: Latin America Fertility Drugs Market Value (USD billion), by Drug, 2025 & 2034
- Figure 47: Latin America Fertility Drugs Market Value Share (%), by Drug, 2025
- Figure 48: Latin America Fertility Drugs Market Value (USD billion), by Treatment, 2025 & 2034
- Figure 49: Latin America Fertility Drugs Market Value Share (%), by Treatment, 2025
- Figure 50: Latin America Fertility Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 51: Latin America Fertility Drugs Market Value Share (%), by Route of Administration, 2025
- Figure 52: Latin America Fertility Drugs Market Value (USD billion), by End User, 2025 & 2034
- Figure 53: Latin America Fertility Drugs Market Value Share (%), by End User, 2025
- Figure 54: Latin America Fertility Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 55: Latin America Fertility Drugs Market Value Share (%), by Country/ Sub-region, 2025
- Figure 56: Middle East & Africa Fertility Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 57: Middle East & Africa Fertility Drugs Market Value Share (%), by Drug Class, 2025
- Figure 58: Middle East & Africa Fertility Drugs Market Value (USD billion), by Drug, 2025 & 2034
- Figure 59: Middle East & Africa Fertility Drugs Market Value Share (%), by Drug, 2025
- Figure 60: Middle East & Africa Fertility Drugs Market Value (USD billion), by Treatment, 2025 & 2034
- Figure 61: Middle East & Africa Fertility Drugs Market Value Share (%), by Treatment, 2025
- Figure 62: Middle East & Africa Fertility Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 63: Middle East & Africa Fertility Drugs Market Value Share (%), by Route of Administration, 2025
- Figure 64: Middle East & Africa Fertility Drugs Market Value (USD billion), by End User, 2025 & 2034
- Figure 65: Middle East & Africa Fertility Drugs Market Value Share (%), by End User, 2025
- Figure 66: Middle East & Africa Fertility Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 67: Middle East & Africa Fertility Drugs Market Value Share (%), by Country/ Sub-region, 2025
- Figure 68: Global Fertility Drugs Market Share (%), by Company, 2025
